top of page
Search

Enteral Feeding Formulas Market Demand, Share & Growth Trends 2034

  • Writer: Pallavi Garudkar
    Pallavi Garudkar
  • Mar 17
  • 3 min read
Enternal Feeding Formulas Market
Enternal Feeding Formulas Market

According to Fortune Business Insights the global enteral feeding formulas market size was valued at USD 8.31 billion in 2025. The market is projected to grow from USD 8.75 billion in 2026 to USD 13.79 billion by 2034, exhibiting a CAGR of 5.85% during the forecast period. Enteral feeding formulas are specialized liquid nutritional products administered through the gastrointestinal tract, either orally or via feeding tubes, for patients who cannot consume adequate nutrition through normal eating. These formulas are widely used in hospitals, home care settings, and long-term care facilities for patients suffering from chronic illnesses, malnutrition, or post-surgical recovery.

Market Insights

  • Increasing prevalence of chronic diseases such as cancer, diabetes, and neurological disorders is driving demand for enteral nutrition.

  • Growing aging population globally is a major factor contributing to market expansion.

  • Rising demand for home healthcare and long-term care services is boosting adoption of enteral feeding formulas.

  • Technological advancements in disease-specific and plant-based nutritional formulas are improving patient outcomes.

  • Increasing awareness of clinical nutrition and patient recovery support is accelerating market growth.

Market Segmentation

By Product Type

  • Standard Formulas

  • Disease-Specific Formulas

  • Peptide-Based Formulas

  • Immune-Modulating Formulas

  • Blenderized Formulas

Standard formulas dominate the market due to their cost-effectiveness and widespread use across patient groups.

By Age Group

  • Adult

  • Pediatric

The adult segment holds the largest share, driven by high incidence of chronic diseases and age-related health conditions.

By Application

  • Oncology (Cancer Care)

  • Gastroenterology

  • Neurology

  • Diabetes

  • Critical Care

  • Others

The oncology segment represents a major share due to the high nutritional requirements of cancer patients.

By End User

  • Hospitals

  • Long-Term Care Facilities

  • Home Care Settings

Hospitals and long-term care facilities dominate, while home care is the fastest-growing segment.

Regional Insights

  • North America: North America dominates the enteral feeding formulas market due to advanced healthcare infrastructure, high healthcare expenditure, and strong demand for clinical nutrition products. The region holds a significant share of over 30%.

  • Asia Pacific: Asia Pacific is expected to be the fastest-growing region due to rising healthcare awareness, increasing elderly population, and growing prevalence of chronic diseases in countries such as China, Japan, and India.

  • Europe: Europe represents a significant market due to increasing adoption of specialized nutrition products and advancements in healthcare systems.

  • Rest of the World: Regions such as Latin America, the Middle East, and Africa are witnessing gradual growth due to improving healthcare infrastructure and rising demand for nutritional therapies.

Competitive Analysis

The enteral feeding formulas market is moderately competitive with global healthcare and nutrition companies competing through innovation and product development.

Key competitive strategies include:

  • Development of disease-specific and personalized nutrition formulas

  • Expansion into home healthcare and outpatient nutrition markets

  • Investment in clinical research and product innovation

  • Strategic partnerships with hospitals and healthcare providers

Companies are also focusing on clean-label, allergen-free, and plant-based formulations to meet evolving consumer preferences.

LIST OF KEY ENTERAL FEEDING FORMULAS COMPANIES PROFILED

  • Abbott (U.S.)

  • Nestlé Health Science (Switzerland)

  • Nutricia (France)

  • Fresenius Kabi (Germany)

  • Braun (Germany)

  • Baxter (U.S.)

  • Ajinomoto Co., Inc. (Japan)

  • Otsuka Pharmaceutical Co., Ltd. (Japan)

Key Industry Development:

  • June 2025: Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A. enrolled the first infants in the FIT-PIV Phase 3 clinical trial. This study is evaluating the safety and effectiveness of ELGN-2112, an investigational drug candidate aimed at treating intestinal malabsorption in preterm infants.

  • January 2025: Otsuka Pharmaceutical Factory, Inc., launched ENOSOLID semi-solid for enteral use.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights Pvt. Ltd.

9th Floor, Icon Tower,

Baner - Mahalunge Road, Baner,

Pune-411045, Maharashtra, India.

Phone:

US: +18339092966

UK: +448085020280

APAC: +91 744 740 1245Email: sales@fortunebusinessinsights.com


 
 
 

Comments

bottom of page